Boron neutron capture therapy at the University of Missouri using select purpose-built compounds
Metadata[+] Show full item record
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Boron Neutron Capture Therapy (BNCT) of multiple cancer lines is demonstrated in mice using unilamellar liposomes as a boron delivery vehicle. BNCT is a form of cancer treatment which provides specific killing of cancer cells by the selective distribution of boron in the patient followed by irradiation with thermal neutrons. The liposomes used in the study contain purpose-built boron compounds characterized at the University of Missouri. The research herein includes studies evaluating the biodistribution and treatment efficacy of various boron compound formulations, as well as neutron dosimetry in canine models. The boron is best delivered as two separate 200 ?L injections into the lateral tail vein, 24 hours apart. Using this injection scheme, followed by a 45 minute irradiation, growth to tumor size 500 mm3 is delayed 2.67 times (20 days) in treated mice bearing EMT6 tumors, and 5.86 times (34 days) in treated mice bearing CT26 tumors when compared with untreated controls. These results are not significantly different when the dose is delivered in two separate fractions. Additionally, these results were obtained with minimal identifiable side effects to the mice. These works also demonstrate therapeutic BNCT in tumor-bearing mice using a newly synthesized boron nanoparticle developed using natural-abundance boron starting materials. The data presented in the neutron osimetry studies demonstrate that clinical BNCT of canine patients using the existing thermal neutron beam at MURR is feasible with appropriate case selection. This data can be used in future studies to verify computer modeling using BNCT planning software.--From public.pdf
Access is limited to the campus of the University of Missouri--Columbia.